| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-07-12 | ODS2004436 | lung cancer | 1 | Oncodesign (France) | Cancer - Oncology |
| 2016-07-12 | EBV-CTL | EBV-Associated lymphomas and lymphoproliferative disorders | N/A | Atara Biotherapeutics (USA - CA) | Cancer - Oncology - Transplantation |
| 2016-07-11 | MYK-461 | hypertrophic cardiomyopathy | 1 | Myokardia (USA - CA) | Cardiovascular diseases |
| 2016-07-11 | CDX-014 | advanced renal cell carcinoma (RCC). | 1-2 | Celldex Therapeutics (USA - NJ) | Cancer - Oncology |
| 2016-07-11 | masitinib | amyotrophic lateral sclerosis | preclinical | AB Science (France) | Rare diseases - Neurodegenerative diseases |
| 2016-07-09 | Vacc-4x and Istodax® (romidepsin) | HIV infection | 1-2 | Bionor Pharma (Norway) Celgene (USA - NJ) | Infectious diseases |
| 2016-07-09 | ARC-521 | chronic hepatitis B | 1-2 | Arrowhead Research Corporation (USA - CA) | Infectious diseases |
| 2016-07-08 | CCP-08 | cough cold | preclinical | Vernalis (UK) Tris Pharma (USA - NJ) | Respiratory diseases |
| 2016-07-08 | roxadustat | anemia associated with chronic kidney disease (CKD) | 2 | FibroGen (USA - CA) | Kidney diseases - Renal diseases |
| 2016-07-08 | Sutent® (sunitinib) | patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery | 3 | Pfizer (USA - NY) | Cancer - Oncology |
| 2016-07-07 | dual orexin receptor antagonist (DORA) | insomnia | 2 | Actelion (Switzerland) | CNS diseases |
| 2016-07-07 | Zika virus vaccine | Zika virus infection | Valneva (France- Austria) | Infectious diseases | |
| 2016-07-07 | Soliris® (eculizumab) | refractory generalized myasthenia gravis (MG) | 3 | Alexion Pharmaceuticals (USA - CT) | Rare diseases - Genetic diseases - Neuromuscular diseases |
| 2016-07-07 | ALN-HBV | Hepatitis B iInfection | 1-2 | Alnylam Pharmaceuticals (USA - MA) | Infectious diseases |
| 2016-07-07 | LusiNEX, biosimilar version of RoActemra® (tocilizumab) | rheumatoid arthritis | 1 | Mycenax Biotech (Taiwan) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-07-06 | CDKL5 program | cyclin-dependent kinase-like 5 (CDKL5) deficiency | preclinical | Amicus Therapeutics (USA - NJ) | Rare diseases - Genetic diseases - Neurological diseases |
| 2016-07-06 | pediatric formulation of Opsumit® (macitentan) | pulmonary arterial hypertension | 3 | Actelion (Switzerland) | Rare diseases - Cardiovascular diseases - Autoimmune diseases |
| 2016-07-06 | AZD4635 ( HTL1071) and durvalumab (MEDI4736) | advanced solid malignancies, non small cell lung cancer | 1 | AstraZeneca (UK) | Cancer - Oncology |
| 2016-07-06 | MM-151 | advanced solid tumors, colorectal cancer, squamous cell head and neck cancer, non small cell lung cancer, triple negative breast cancer | 1 | Merrimack Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2016-07-06 | avelumab (MSB0010718C) | ovarian cancer | 3 | Pfizer (USA - NY) Merck KGaA (Germany) | Cancer - Oncology |
